Substance / Medication

Factor I

Overview

Active Ingredient
fibrinogen
RxNorm CUI
4385

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Complete Complement Factor I (CFI) deficiency: a systematic review of forty-nine patients including three novel cases.
Rajabi Erta, Kheirabadi Mahsa Choroom, Olyaei Nasrin Alipour et al. · BMC Immunol · 2025
PMID: 40713518Meta-AnalysisFull text (PMC)
Genetically predicted insulin-like growth factor-I in relation to muscle mass and strength.
Yuan Shuai, Larsson Susanna C · Clin Endocrinol (Oxf) · 2021
PMID: 34293202Meta-Analysis
The nuclear factor I/A (NFIA) gene is associated with the asthma plus rhinitis phenotype.
Dizier Marie-Hélène, Margaritte-Jeannin Patricia, Madore Anne-Marie et al. · J Allergy Clin Immunol · 2014
PMID: 24560411Meta-Analysis
Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.
Beauverd Michel, Mitchell J D, Wokke John H J et al. · Cochrane Database Syst Rev · 2012
PMID: 23152212Meta-AnalysisFull text (PMC)
Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.
Burgers Anne Marij G, Biermasz Nienke R, Schoones Jan W et al. · J Clin Endocrinol Metab · 2011
PMID: 21795450Meta-Analysis
Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review.
Qin Li-Qiang, He Ka, Xu Jia-Ying · Int J Food Sci Nutr · 2009
PMID: 19746296Meta-Analysis
Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels.
Johansson Mattias, McKay James D, Wiklund Fredrik et al. · J Clin Endocrinol Metab · 2007
PMID: 17911177Meta-Analysis
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Mitchell J D, Wokke J H J, Borasio G D · Cochrane Database Syst Rev · 2007
PMID: 17943766Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Factor I (substance)
SNOMED CT
259790000
UMLS CUI
C0016006
RxNorm CUI
4385

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.